About this trial
The Primary Objective of this study is to evaluate the efficacy and safety of teniposide in combination with temozolomide for the treatment of newly diagnosed glioblastoma (nGBM) with MGMT promotor region unmethylated.
The study will also assess the safety of teniposide combined with temozolomide. The primary questions to be addressed include:
* Does the treatment demonstrate efficacy for the disease under study? * What medical problems or adverse events may participants experience while receiving the study drugs?
Participants will:
* Receive teniposide: 60 mg/m² in 500 mL of normal saline, administered as an intravenous infusion over at least 30 minutes, once daily on Days 1-3 of each cycle. Each cycle is 28 days, for a total of 6 cycles.Receive temozolomide (TMZ) orally: 150 mg/m² once daily for 5 days during Cycle 1; starting from Cycle 2, the dose will be increased to 200 mg/m² once daily for 5 days. Each cycle is 28 days, for a total of 6 cycles. * Visit the hospital for assessments at each cycle. * Have their medication adherence and assessment results recorded.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
1. Newly diagnosed with glioblastoma (nGBM), histopathologically confirmed according to the 2021 WHO Classification of Tumors of the Central Nervous System.
Disqualifiers
1. Early progressive disease following the completion of TMZ/RT (including patients with suspected pseudoprogression).
Trial design
Single group
Treatments tested in this trial
Teniposide Combined with Temozolomide
DrugReceive teniposide: 60 mg/m² in 500 mL of normal saline, administered as an intravenous infusion over at least 30 minutes, once daily on Days 1-3 of each cycle. Each cycle is 28 days, for a total of 6 cycles. Receive temozolomide (TMZ) orally: 150 mg/m² once daily for 5 days during Cycle 1; starting from Cycle 2, the dose will be increased to 200 mg/m² once daily for 5 days. Each cycle is 28 days, for a total of 6 cycles.
Treatment groups
Trial outcomes
Primary outcomes
Median Overall Survival
Median overall survival (mOS) is defined as the time at which half of the cases are still alive, which is the time estimated when the survival rate on the OS survival curve reaches 50%.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: